451 related articles for article (PubMed ID: 10686314)
1. Steroid withdrawal in renal transplant recipients.
Oppenheimer F
Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
[No Abstract] [Full Text] [Related]
2. [Toward an evidence-based immunosuppression].
Pascual J
Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
[No Abstract] [Full Text] [Related]
3. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes BD; Coosemans W; Pirenne J; Vanrenterghem YF
Transplant Proc; 2002 Jun; 34(4):1164-70. PubMed ID: 12072305
[No Abstract] [Full Text] [Related]
4. Improved outcome of steroid withdrawal in mycophenolate mofetil-treated primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M
Transplant Proc; 1999; 31(1-2):1131-2. PubMed ID: 10083505
[No Abstract] [Full Text] [Related]
5. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
Smith JM; Nemeth TL; McDonald RA
Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
[TBL] [Abstract][Full Text] [Related]
6. Minimizing calcineurin inhibitor drugs in renal transplantation.
Flechner SM
Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
[No Abstract] [Full Text] [Related]
8. Maintenance immunosuppression: new agents and persistent dilemmas.
Gonin JM
Adv Ren Replace Ther; 2000 Apr; 7(2):95-116. PubMed ID: 10782729
[TBL] [Abstract][Full Text] [Related]
9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
10. Selective CellCept therapy in high-risk renal transplant recipients.
Isenberg A; Singh TP; Shen GK; Freed BM; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
[No Abstract] [Full Text] [Related]
11. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
12. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
[No Abstract] [Full Text] [Related]
13. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group.
Stratta RJ
Transplant Proc; 1997; 29(1-2):654-5. PubMed ID: 9123463
[No Abstract] [Full Text] [Related]
15. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
16. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients.
Blume C; Hollenbeck M; Ivens K; Heering P; Hetzel GR; Grabensee B
Transplant Proc; 2001; 33(7-8):3161-3. PubMed ID: 11750357
[No Abstract] [Full Text] [Related]
17. Steroid withdrawal in kidney transplantation: the subgroup fallacy.
Steiner RW
Transplantation; 2011 Mar; 91(5):e27-8. PubMed ID: 21336084
[No Abstract] [Full Text] [Related]
18. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
Leichtman AB
N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
[No Abstract] [Full Text] [Related]
19. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
[No Abstract] [Full Text] [Related]
20. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
